Interpolymer interactions between the countercharged polymers like Eudragit® EPO (polycation) and hypromellose acetate succinate. PDF | The objective of this investigation was to evaluate the potential of Eudragit EPO nanoparticles (EPO NP) in improving therapeutic efficacy. Download scientific diagram | Molecular structures of (a) MFA, (b) EUDRAGIT® EPO, and (c) EUDRAGIT® L from publication: Stabilization of a.
|Published (Last):||6 July 2016|
|PDF File Size:||3.31 Mb|
|ePub File Size:||3.41 Mb|
|Price:||Free* [*Free Regsitration Required]|
The hardness of the matrix tablets was examined for five tablets of each batch using a hardness tester Dr. The eudragih friability was calculated using the following equation: FT-IR spectrum of pure polymers. This slower drug release performance could be attributed to the PEC formation at this pH.
Where n is the number of pull points, R t is the reference profile at time point tand T t is the test profile at the same time point; the value of f 2 should be between 50 and The increase in polymer concentration resulted in an increase of the MDT values, where for mg polymer concentration the MDT value was 4. Thus, it can be concluded that the use of single anionic or cationic polymer will not provide sustained drug release from the matrix tablets.
Acknowledgments The authors are grateful to Mylan laboratories Limited, Hyderabad, India, for the generous gift samples of acetaminophen and excipients. The swelling of the polymers upon hydration by the test medium was determined by a method similar to the equilibrium weight gain method as reported earlier In Vitro Drug Release In vitro drug release testing from tablets was conducted according to the USP 27 apparatus 2 specifications using a dissolution tester Electrolab, India.
The drug release profiles were compared using two model-independent methods, mean dissolution time MDTand similarity factor f 2 Data sheets for overmetals, plastics, ceramics, and composites.
We advise that you only use the original value or one of its raw conversions in your calculations to minimize rounding error. Polymethacrylate polymers have been widely used in pharmaceutical formulations as film-coating agent and as matrix carriers in solid dispersion preparation and in hot-melt extrusion processes 13 — The prolonged drug release from the matrix system could be better explained by the in situ formation of PEC.
The product, PEC complex, was isolated and then dried, before being utilized as a polymeric carrier for modified drug release Swelling Studies The swelling of the polymers upon hydration by the test medium was determined by a method similar to the equilibrium weight gain method as reported earlier It is well known that the release properties of polymeric carriers can be somehow predicted by the determination of their swelling and erosion characteristics Eur J Pharm Sci.
Release Profile Comparison The drug release profiles were compared using two model-independent methods, mean dissolution time MDTand similarity factor f 2 Use of hydroxypropyl methylcellulose acetate succinate in an enteric polymer matrix to design controlled-release tablets of amoxicillin trihydrate.
To clarify the release exponent for different batches of matrices, the log value of percentage drug released was plotted against log time for each batch according to the Eq.
Evonik Pharma polymers This slow release is because of the formation of a stronger PEC gel structure that delays drug release from the tablet matrix.
The effect of dissolution media pH 1. American Pharmacists Association; Subscribe to Premium Services Searches: Chemical structure of a EL and b EE polymer. The performance of the in situ formed PEC as a matrix for controlled release of drugs was evaluated, using acetaminophen as a model drug.
Published online Jan Indian J Pharm Sci. The spectrum of EL Fig. Ehdragit the total amount of polymers in the formulation from mg F10 to mg F9 and mg F8 resulted in a slower release rate and extended drug release from the tablet. The dissolution testing for acetaminophen was conducted in ml of 0.
The rate of swelling was found to be different for different polymer combinations, and this could be attributed to the different drug release profiles and mechanisms observed during the dissolution analysis of matrix tablets. The model with the highest correlation coefficient was considered to be the best-fitting one.
There was a problem providing the content you requested
The f 2 values determined by comparing drug release profiles in pH 1. Users requiring more precise data for scientific or engineering calculations can click on the property value to see the original value as well as raw conversions to equivalent units. These profiles could be controlled by conveniently modifying the proportion of the polymer ratio, polymer type, and polymer concentration the in the tablets.
The swelling study was done in triplicate for all samples tested. To study the release kinetics, data obtained from in vitro drug release studies were plotted in various kinetic models: The drug content was determined spectrophotometrically at a wavelength of nm.
Dissolution of tablets prepared using different polymer concentrations in pH 6. To study the effect of anionic and cationic polymer ratio and polymer concentration on the release profile of the drug from the matrix system. Ho C, Hwang GC.
Evonik EUDRAGIT® E PO Copolymer
The release rate was slowest for the higher polymer concentration formulation F8 with a K value of 7. Various types of oppositely charged polyelectrolytes interact electrostatically in eudtagit media to form an insoluble solid or PEC 2 — 5.
Other Engineering Eudragig Material Notes: The dissolution data of these matrices were fitted to different dissolution models. To study the effect of enteric polymer type on the release profile of the drug from the matrix system. Handbook of pharmaceutical excipients.